Previous Article | Next Article 
Journal of Virology, January 2000, p. 49-56, Vol. 74, No. 1
0022-538X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Extended Analysis of the In Vitro Tropism of
Porcine Endogenous Retrovirus
Carolyn A.
Wilson,1,*
Susan
Wong,1
Matthew
VanBrocklin,2 and
Mark J.
Federspiel2
Division of Cellular and Gene Therapies,
Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, Maryland 20892,1 and
Molecular Medicine Program, Mayo Clinic and Mayo
Foundation, Rochester, Minnesota 559052
Received 30 July 1999/Accepted 21 September 1999
 |
ABSTRACT |
We previously reported that mitogenic activation of porcine
peripheral blood mononuclear cells resulted in production of porcine endogenous retrovirus(es) (PERV[s]) capable of productively infecting human cells (C. Wilson et al., J. Virol. 72:3082-3087, 1998). We
now extend that analysis to show that additional passage of isolated
virus, named here PERV-NIH, through a human cell line yielded a viral
population with a higher titer of infectious virus on human cells than
the initial isolate. We show that in a single additional passage on a
human cell line, the increase in infectivity for human cells is
accounted for by selection against variants carrying pig-tropic
envelope sequences (PERV-C) as well as by enrichment for
replication-competent genomes. Sequence analysis of the envelope cDNA
present in virions demonstrated that the envelope sequence of PERV-NIH
is related to but distinct from previously reported PERV envelopes. The
in vitro host range of PERV was studied in human primary cells and cell
lines, as well as in cell lines from nonhuman primate and other
species. This analysis reveals three patterns of susceptibility to
infection among these host cells: (i) cells are resistant to infection
in our assay; (ii) cells are infected by virus, as viral RNA is
detected in the supernatant by reverse transcription-PCR, but the cells are not permissive to productive replication and spread; and (iii) cells are permissive to low-level productive replication. Certain cell
lines were permissive for efficient productive infection and spread.
These results may prove useful in designing appropriate animal models
to assess the in vivo infectivity properties of PERV.
 |
INTRODUCTION |
Clinical trials are ongoing to test
the feasibility of using porcine cells or tissues as a viable
alternative to the transplantation of their human counterparts. These
trials are intended to form the groundwork for the general use of
pig-derived cells or organs as a means to circumvent the increasingly
inadequate supply of human organs. The impending application of porcine
to human xenotransplantation on a widespread basis brings with it the
possibility of introducing an infectious agent from the pig into the
xenograft recipient and, ultimately, to the public. Extensive screening
of source animals may provide animals free of certain exogenous agents. However, endogenous agents and those agents that current detection strategies do not identify may still be harbored in the porcine xenograft. For this reason, there is renewed interest in studying the
biology of porcine endogenous retroviruses (PERVs).
We have previously shown that mitogenic activation of primary
peripheral blood mononuclear cells (PBMC) of pigs results in the
release of PERV(s) directly infectious for human cells (18). Other reports have shown that the pig kidney cell lines PK-15 and MPK
spontaneously express retrovirus infectious for pig cells (2, 6,
11, 15), and later it was shown that the PK-15-derived virus
could also infect human cell lines (11). More recently, it
was also demonstrated that primary cultures of porcine endothelial cells spontaneously express PERVs capable of infecting human cells (7).
To gain insight into the in vivo biology and potential for PERV
pathogenesis, it is critical to develop an animal model. Inherent in
this process is the need to know what species are susceptible to
infection by PERV. Analysis of in vitro susceptibility is a cost-effective and rapid way to screen a number of different species in
order to make a more informed choice on an appropriate in vivo model.
However, in vitro infection may not always correlate to in vivo
infectivity. For example, gibbon ape leukemia virus can infect rat cell
lines in vitro (16, 19), but rats are not susceptible to
infection in vivo (3). Alternatively, a species may be
susceptible to infection in vivo, but a derivative cell line(s) may not
be sensitive to infection by a given virus. As one example, mice are
the natural host for Moloney murine leukemia virus, yet certain murine
cell lines, such as a nonpermissive murine teratocarcinoma cell line
(10), will not support replication in vitro.
Host range analyses initially showed that PERVs are restricted in their
species tropism, infecting only porcine cells and not cell lines
derived from a range of species including chimpanzee, rhesus monkey,
horse, mink, bat, rabbit, cow, cat, dog, and mouse (15).
Subsequent molecular analysis of the envelope-coding sequences of PERV
has demonstrated that there are at least three different classes of
envelope, currently named A, B, and C (1, 4, 13). Takeuchi
and coworkers (13) generated pseudotypes composed of murine
leukemia virus retroviral vector genomes and core proteins bearing
different PERV-derived envelope glycoproteins in order to determine
what cell types express functional receptors for PERVs bearing any one
of these three classes of envelope. Their studies demonstrated that
cell lines derived from mink, mouse, rat, rabbit, bat, hamster, dog,
and cat were susceptible to infection by one or more of the pseudotypes
bearing one of these three classes of PERV envelopes (13).
While these data demonstrate that a functional receptor for one of the
three PERV envelopes exists on those cell lines, they do not
necessarily imply that all cells examined are permissive for viral replication.
In this study, we have used a combination of pseudotypes and wild-type
virus to determine whether susceptibility to infection by PERV
pseudotype correlates with permissiveness to productive replication by
PERV. We used this approach to analyze a range of human and nonhuman
primary cells and cell lines. The results presented here have
implications for development of appropriate approaches for monitoring
recipients of porcine xenotransplants as well as for the analysis of
candidate animal models for studying the in vivo infection properties
of PERV.
 |
MATERIALS AND METHODS |
Primary cells and cell lines.
The cell lines used in this
study were obtained from the American Type Culture Collection (ATCC)
unless otherwise indicated. 293 human embryonic kidney (ATCC CRL-1573),
MMK Mus musculus molossinus kidney (ATCC CRL-6439; no longer
available), and SC-1 mouse embryo epithelial (ATCC CRL-6450) cells,
MDTF Mus dunni tail fibroblasts (kindly provided by Olivier
Danos), NRK normal rat kidney cells (ATCC CRL-6509), Rat-2 rat embryo
fibroblasts (ATCC CRL-1764), SIRC rabbit corneal fibroblasts (ATCC
CCL-60), D17 canine oseosarcoma (ATCC CRL-6248), MDBK bovine kidney
epithelium (ATCC CCL-22), FRhK4 rhesus monkey kidney (ATCC CRL-1688),
Mv1Lu mink lung epithelial (ATCC CCL-64), and MiCL.1 (S+L
) mink lung
(ATCC CCL-64.1) cells, Fc3TG feline tongue fibroblasts (ATCC CCL 176),
and AK-D feline lung epithelial (ATCC CCL-150), CRFK feline kidney
epithelial (ATCC CCL-94), CaKi-1 clear cell kidney carcinoma (ATCC
HTB-46), HeLa cervical adenocarcinoma (ATCC CCL-2), HOS human
osteosarcoma (ATCC CRL-1543), and CaCO-2 colorectal adenocarcinoma
(ATCC HTB-37) cells were maintained in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine,
1 mM sodium pyruvate, 100 U of penicillin per ml, and 100 µg of
streptomycin per ml. PG-4 feline glial cells and astrocytes (ATCC CRL
2032) were maintained in McCoy's 5A medium supplemented with 15% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U of penicillin per ml, and
100 µg of streptomycin per ml. HepG2 hepatoblastoma (ATCC HB-8065)
and HT1080 fibrosarcoma (ATCC CCL-121) cells were maintained in
Eagle's modified essential medium supplemented in a similar manner.
The following cell lines were maintained in RPMI 1640 supplemented with
10% FBS, 2 mM glutamine, 0.05 mg of gentamicin sulfate per ml, and 1×
nonessential amino acids (Biofluids, Rockville, Md.): Molt 4 acute
lymphoblastic (ATCC CRL-1582), Daudi Burkitt's lymphoma (ATCC
CCL-213), Raji Burkitt's lymphoma (ATCC CCL-86), and U937 histiocytic
lymphoma (ATCC CRL 1593.2) cells, UCLA-SO-M14 T cells (12),
and human natural killer YTN10 (20) cells.
Derivation of viral pseudotypes.
Cells productively infected
with PERV-NIH, derived originally from activated PBMC of NIH minipigs
(pPBMC) (18), were superinfected with retrovirus
vector-containing supernatant harvested from PA317/G1BgSvN (9) in a manner similar to that previously described
(5). The resulting PERV pseudotypes carry the murine
retrovirus genome, G1BgSvN, coated by PERV core and envelope proteins.
G1BgSvN-containing cells were selected in 187 µg of G418 (active
component) per ml. After 10 to 14 days of selection, G418-resistant
colonies were pooled and used to generate viral pseudotypes. Since the
G1BgSvN vector genome contains the coding sequences for both neomycin phosphotransferase and
-galactosidase (9), pseudotype
infection can be monitored by the acquisition of target cell resistance to G418 or by immunohistochemical detection of target cells expressing
-galactosidase.
EM examination for enumeration of virus particles.
Ten-milliliter aliquots of virus-containing supernatants were prepared
for electron microscopic (EM) examination by ultracentrifugation through a 20% sucrose cushion in 50 mM Tris (pH 8.0) at
150,000 × g. Viral pellets were resuspended in 100 µl of Dulbecco modified Eagle medium without additives, representing
a 100-fold concentration of the samples. Samples were prepared for and
examined by negative stain transmission EM by Advanced Biotechnologies,
Inc. (Columbia, Md.), to determine particle counts.
Infectivity assays.
Supernatant infections were used to
determine the infectivity of cell-free virus derived from different
producer cell lines. Comparisons between fresh and frozen
virus-containing supernatants demonstrated that storage of viral
supernatants at
70°C resulted in >100-fold decrease in infectious
titer (data not shown). Therefore, all experiments were performed with
freshly harvested supernatant. On the day prior to initiation of an
infectivity assay, target cells were seeded at 3 × 104 to 5 × 104 cells per well in 12-well
dishes. On the next day, supernatants from confluent cultures of virus
producer cells were harvested, filtered through a 0.45-µm-diameter
filter, adjusted to 6 µg of Polybrene per ml, and used to replace the
medium on target cells. On the following day, the cells were fed with
fresh medium. When
-galactosidase expression was used to monitor
infectivity, the cells were fixed and histochemically stained 48 to
72 h after exposure to viral supernatant and observed
microscopically to enumerate blue-staining focus-forming units (BFU)
per milliliter as previously described (17). If the
experiment was performed to assess productive infection of the target
cell, the cells would be passaged one or two times per week as needed
during the course of the experiment and monitored as described below.
The coculture of target cells with virus producer cells was used to
assess the ability of the virus to be transmitted to nonadherent cells.
Since several different cell types were used as a source of virus
producer cells in these experiments, the dosage of irradiation required
to ensure that the virus producer cells would die within 5 days after
irradiation was first determined. For this, 3 × 106
to 4 × 106 cells for each virus-producer cell line
were exposed to 2,000, 5,000, or 10,000 rads (using a 137Cs
source [Nordion GammaCell 1000]) and seeded into a 96-well plate at
2 × 105 to 3 × 105 cells/well.
Irradiated and control nonirradiated cells were monitored for
proliferation daily for 5 days by measuring [3H]thymidine
uptake after cells were cultured for 8 h with 1.0 µCi of
[3H]thymidine (6.7 Ci/mmol; Dupont NEN, Boston, Mass.),
harvested onto glass filters (Skatron, Sterling, Va.), placed in
scintillant, and counted (Wallac, Turku, Finland). The lowest
irradiation dose where no proliferation was measured during the 5 days
of assay was used in the coculture experiments; Daudi cells received
2,000 rads, Molt 4 cells received 5,000 rads, and U937 cells received 7,000 rads.
When the target cells in the coculture were human PBMC (hPBMC), the
mononuclear layer was collected from a buffy coat from
a human donor
separated by lymphocyte separation medium (Organon
Teknika, Durham,
N.C.). Cells were stimulated in 1× phytohemagglutinin
(PHA) as
instructed by the manufacturer (Life Technologies, Gaithersburg,
Md.)
for 3 days and then mixed in a 1:1 ratio with 3 × 10
6
lethally irradiated virus producer cells in 12-well dishes. Thereafter,
the cocultures were maintained in RPMI 1640 medium supplemented
with
10% FBS, 10% purified human interleukin-2 (IL-2; Boehringer
Mannheim), 10 ng of recombinant human IL-2 (Chiron Corporation,
Emeryville, Calif.) per ml, 2 mM glutamine, 100 U of penicillin
per ml,
and 100 µg of streptomycin per ml. Control wells containing
only
irradiated virus producer cells were monitored for cell viability
by
visualizing samples microscopically for trypan blue exclusion.
Cocultures containing 293 cells as target cells were carried out
in
parallel as a control for the infectivity of the virus producer
cells.
The day after initiation of the coculture, the medium was
replaced with
fresh medium and cells were subcultured once or
twice per week as
needed. Cocultures containing the hPBMC as targets
were reinfused every
2 weeks with freshly stimulated hPBMC from
the same buffy coat of
cells.
Methods used to monitor virus infection of target cells.
Infection of target cells was assessed by one of three methods. All
infectivity experiments included parallel mock-infected cultures as
negative controls that were subject to the same analyses as
virus-exposed cultures. In some cases, the titer of infectious virus
pseudotypes was determined by
-galactosidase expression. Cells were
histochemically stained 48 to 72 h after exposure to virus-containing supernatant, and titers (BFU per milliliter) were
determined. Those titers were then normalized to the titer observed on
293 cells exposed to the same viral supernatant and are reported as
percentage of control. The titer observed on 293 cells ranged from
several hundred to 3,000 BFU/ml in different experiments.
Periodic samples of the supernatant from confluent cultures for reverse
transcriptase (RT) activity were used to monitor infection
of wild-type
viruses. Supernatant samples were examined for RT
activity as
previously described (
18).
RT-PCR analysis was used to assess the presence of viral RNA in cells
exposed to PERV. RNA was extracted from cell culture
supernatant by
using RNA STAT 50-LS (Tel-Test "B", Inc., Friendswood,
Tex.) and
coprecipitated with 6.6 µg of tRNA. RNA was reverse
transcribed with
SuperscriptII as instructed by the manufacturer
(Life Technologies),
using 50 ng of random primers (Life Technologies).
The cDNA was then
amplified by PCR using primers specific to the
pol region of
the virus genome (GenBank accession no.
AF033259),
PB906 (5'
ACGTACTGGAGGAGGGTCACCTGA 3') and PB908 (5'
GTCCCGAACCCTTATAACCTCTTG
3'). The PCR products were fractionated
on a 1% agarose gel, followed
by Southern blotting and hybridization
of the amplified products,
using conditions as previously described
(
18).
Molecular analysis of envelope cDNAs.
Virus was concentrated
from 100 ml of supernatant from PERV-NIH-1° or PERV-NIH-3° or
PERV-NIH-2° virus producer cell lines by centrifugation of precleared
cell supernatant as described elsewhere (17). The virus
pellet was solubilized in RNA STAT-60 (Tel-Test "B"), extracted
(according to the manufacturer's instructions), and coprecipitated
with 6.6 µg of tRNA. Viral RNA was reverse transcribed as described
above. To determine the envelope subgroup specificity of the envelope
cDNA, the following primer pairs were used in a PCR: PL170 and PL171
for detection of PERV-A (GenBank accession no. Y12238) (4);
PL-172 and PL-173 for detection of PERV-B (GenBank accession no.
Y12239) (4); and MSL-1 (5' CTGACCTGGATTAGAACTGGAAGC 3')
and MSL-2 (5' AGAGGATGGTCCTGGTCCTTGGGA 3') for
detection of PERV-C (GenBank accession no. AF038600) (1).
The fragments were amplified as follows: 30 cycles at 94°C for
30 s, 55°C for 30 s, and 72°C for 1 min after an initial 1-min denaturation step at 94°C After fractionation of the PCR products on an agarose gel, the DNA fragments were immobilized onto
Nytran by Southern blot transfer and hybridized under the following
conditions. For detection of PERV-A envelope-specific sequences, a PCR
fragment derived by amplification of an envelope expression plasmid by
using primers PERVenv3 (5' CTTTTGACCACACCAACGGCTGTG 3') and
PERVenv4 (5' CCTTTCATTCCC CACTACTTGTC 3') (GenBank accession no. Y12238) was gel purified, nick translated, and hybridized in
Hybrisol at 42°C. The blot was then washed in 2× SSC (1× SSC is
0.15 M NaCl plus 0.015 M sodium citrate)-with 0.1% sodium dodecyl sulfate (SDS) at room temperature for 15 min, followed by washing in
0.1× SSC-0.1% SDS at 65°C for 15 min. For detection of
PERV-B-specific (GenBank accession no. Y12239) and PERV-C-specific
(GenBank accession no. AF038600) sequences, the oligonucleotides PERV-B (5' GGGACGAGGGTCCACTTTAACCATTCGCCTTAGGATAGAG 3') and MSL-3
(5' CAGCTGGAGCCTCCAATGGCTATAGGACCAAATACGGTC 3'),
respectively, were end labeled with [
-32P]dATP
by using T4 polynucleotide kinase. The oligonucleotide probes were
hybridized in 6× SSC-10 mM NaH2PO4-0.4%
SDS-500 g of sheared DNA per ml at 42°C and then washed in 6×
SSC-0.1% SDS at room temperature for 15 min and at 65°C for 15 min.
Hybridizing DNA fragments were then visualized with a
PhosphorImager (Molecular Dynamics).
For sequence analysis of the envelope cDNAs, a region encoding the
envelope was amplified by using PCR primers from conserved
regions in
the noncoding regions flanking the envelope-coding
region, based on an
alignment of the PERV-A and PERV-B sequences
(
4). PERVenv1
(sense, nucleotides 124 to 144, GenBank accession
no.
Y12238, 5'
ACCTCGAGACTCGGTGGAAG 3') and PERVenv2 (antisense,
nucleotides
2282 to 2259, GenBank accession no.
Y12238, 5'
CTGGGTTCTGGGAGGGTTAGGTTG 3') were used to amplify viral cDNA for
30 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for
1 min
after an initial 1-min denaturation step at 94°C. PCR products
were separated on a 1.0% agarose gel, and DNA fragments of 2 to
2.5 kb
were purified by using a Qiaex gel purification kit (Qiagen,
Valencia,
Calif.). Purified PCR products were then cloned into
the TA vector by
using a TA cloning kit (InVitrogen, Carlsbad,
Calif.). Restriction
analysis of clones derived from the TA vector
was used to ensure the
presence of a 2- to 2.5-kb insert. At least
four representative clones
were chosen for sequence analysis.
All deoxynucleotide sequencing was
performed by the Mayo Clinic
Molecular Biology Core on a Perkin-Elmer
ABI PRISM 377 DNA sequencer
(with XL upgrade) with the ABI PRISM
dRhodamine Terminator Cycle
Sequencing Ready Reaction kit with AmpliTaq
DNA polymerase (PE
Applied Biosystems, Foster City, Calif.). The
ClustalW multiple
sequence alignment program of MacVector 6.0.1 (Oxford
Molecular
Group) was used to compare the deduced envelope amino acid
sequences.
 |
RESULTS |
Passage of a primary isolate of PERV in human 293 cells.
Activated pPBMC were cocultured with human embryonic kidney 293 cells
that became productively infected after 40 to 50 days (18).
We have named the virus produced by the infected 293 cells PERV-NIH-1° and used these cells to passage virus to naive 293 cells
to generate virus referred to here as PERV-NIH-2°. A murine leukemia
virus-based retroviral vector genome, G1BgSvN (9), encoding
-galactosidase and neomycin phosphotransferase, was introduced into
both sets of the 293 virus producer cells to generate virus pseudotypes
carrying a PERV-NIH wild-type genome and/or the G1BgSvN vector genome
(see Materials and Methods). Exposure of target cells to the
pseudotypes allows for quantitative assessment of infectious titer by
detection of
-galactosidase-expressing blue-staining cells after
exposure to a chromogenic substrate. We were then able to use the
expression of
-galactosidase to quantitatively assess the relative
infection efficiency of virus pseudotype produced after initial and
secondary passage of PERV through a human cell line. To analyze whether
additional passage of PERV through human cells might select for a virus
or population of viruses that would more efficiently infect human
cells, we exposed human 293 cells to PERV-NIH-1° or PERV-NIH-2°
pseudotype-containing supernatant. As shown in Table
1, in three experiments, the infectious titers on 293 cells of PERV-NIH-2° pseudotypes were approximately four- to fivefold higher than those observed for the PERV-NIH-1° pseudotypes.
A likely explanation for these observed differences is that the
PERV-NIH-1° virus producer cells carry a higher percentage
of
defective genomes relative to the PERV-NIH-2° virus producer
cells,
which would account for the lower titer of infectious PERV-NIH-1°
virus when exposed to 293 target cells. To assess this possibility,
we
infected 293 cells with supernatant from the PERV-NIH-1° and
PERV-NIH-2° pseudotype producer cell lines. For each supernatant,
samples of input viral supernatant were retained for analysis
of RT
activity and for particle count determination by negative
strain
transmission EM. As shown in Table
2,
particle count enumeration
revealed that PERV-NIH-2° supernatant
contained twofold more particles
than PERV-NIH-1° supernatant, while
the incorporation of [
3H]TTP (a measure of RT activity)
was 4.2-fold higher and there
was an 8.4-fold difference in infectivity
titer on 293 cells.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of RT activities, EM particle counts, and
infectious titers of PERV-NIH-1° and PERV-NIH-2° pseudotypes
containing the G1BgSvN genome
|
|
Analysis of envelope class and coding sequence.
Presence of
the PERV-C envelope in PERV-NIH-1° virions may account for the
discrepancy in the particle/infectivity ratios, since pseudotypes
carrying PERV-C envelopes cannot infect 293 cells (13).
Complementary DNA was synthesized from the RNA of pelleted virions
collected from supernatants of PERV-NIH-1° and PERV-NIH-2° producer
cells. As controls, cellular RNA was also isolated from pPBMC directly
isolated from a Ficoll-Hypaque gradient (unactivated) and from pPBMC
activated in PHA and phorbol myristate acetate (PMA) for 5 days as
previously described (18). Oligonucleotide primers capable
of specifically amplifying each of the PERV envelope classes previously
reported were used to amplify the cDNAs. Products were then hybridized
with probes specific for each of the three envelope classes to enhance
the detection sensitivity (Fig. 1). A
product was detected for all three envelope classes in both unactivated
and activated pPBMC (Fig. 1, lanes 1 and 2). The PERV-A-specific primers and probe detected a PCR product in cDNA from both
PERV-NIH-1° and PERV-NIH-2° virions. No product was observed with
PERV-B-specific primers or probes in either set of cDNAs, although
PERV-B sequences were detected in cDNAs synthesized from both
unstimulated and PHA- and PMA-stimulated pPBMC. The PERV-C-specific
primers and probe generated a product from the PERV-NIH-1° cDNA but
not the PERV-NIH-2° cDNA.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 1.
Detection of PERV envelope classes by RT-PCR of virion
RNA. Viral RNA was examined by RT-PCR from cell lysate derived from
unactivated pPBMC (lane 1) or pPBMC activated with PHA and PMA (lane 2)
(18) or pelleted virions of PERV-NIH-1° (lane 3) or
PERV-NIH-2° (lane 4), using primers specific for each of the envelope
classes indicated. Each primer-specific reaction was fractionated on a
1% agarose gel, transferred to nitrocellulose, and then hybridized to
probes specific for each PERV envelope class listed on the left (see
Materials and Methods). The hybridized products were visualized with a
PhosphorImager.
|
|
We then examined whether subtle progressive changes in the
envelope-coding region may also contribute to the change in infectivity
properties of PERV-NIH-1° relative to PERV-NIH-2°. Of the four
representative clones sequenced from PERV-NIH-1°-derived PCR
amplicons,
three had full open reading frames, and three of six from
the
PERV-NIH-2°-derived PCR amplicons had full open reading frames.
Sequence analysis showed that while each amplicon had nucleotide
changes resulting in alterations in the deduced amino acid sequence,
the predominant envelope expressed in all three virion preparations
is
essentially the same. Figure
2 shows an
alignment of the deduced
amino acid sequence from a representative
clone, 1.15, derived
from cDNA of the PERV-NIH-1° preparation of
virions with the previously
reported sequences for the PERV-A and
PERV-C envelopes. The alignment
shows that the surface glycoprotein
(SU) portion of the envelope
is most similar to the PERV-A class of
envelope (
4), while
the C-terminal 90 amino acid residues of
the transmembrane region
are almost identical to the PERV-C class of
envelope while sharing
only 75% amino acid identity with PERV-A
(
1) (Fig.
2). The
other clones examined contained nucleotide
changes resulting in
altered amino acids in three or four positions; of
these, only
one or two were in SU. Since each clone was unique with
respect
to the changes observed, these alterations most likely
represent
either PCR-induced mutations or the naturally occurring
variance
of the virus populations present in the two virus producer
cell
lines. No change at any specific amino acid residue was ever
observed
in more than one clone, suggesting that there was not a
selection
for a particular envelope, other than the shift from a mix of
PERV-C and PERV-A in the PERV-NIH-1° virus population to only
PERV-A-like envelopes in the PERV-NIH-2° population (Fig.
1).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of amino acid residues encoded by clone
1.15-derived cDNA of 293/PERV-NIH-1° virions (PERV-1.15), PERV-A, and
PERV-C. (A) Schematic representation of regions of the PERV-1.15
envelope homologous to PERV-A (hatched) and PERV-C (open) genes. (B)
Deduced amino acids for the envelope surface glycoprotein (SU; amino
acids 1 to 460) and transmembrane (TM; amino acids 461 to 659) regions
of clone 1.15 derived from cDNA of PERV-NIH-1° virions (GenBank
accession no. AF130444) compared to PERV-A and PERV-C. Identical amino
acids are denoted by dots; gaps are denoted by dashes.
|
|
Analysis of species tropism of PERV.
PERV pseudotypes were
used for an initial screen for susceptibility to infection in a broad
range of cell lines derived from several different species. Target
cells were exposed to the PERV-NIH-2° pseudotype supernatant, and
titers were determined after histochemical staining for
-galactosidase-expressing cells. The relative titers observed on the
tested cell lines normalized to the titers observed on 293 cells are
shown in Table 3. Cell lines derived from
mouse, rat, rabbit, dog, cow, and rhesus monkey were resistant to
infection by PERV-NIH-2° pseudotypes relative to 293 positive
controls, while cell lines derived from cat or mink were susceptible to infection, as measured by this assay. The relative susceptibility of
mink and cat cell lines was low compared with human 293 cells, with the
exception of the MiCl.1 and PG-4 cell lines.
To investigate whether cell lines susceptible to infection by PERV
pseudotypes could also be productively infected by PERV,
the mink and
feline cell lines were exposed to PERV-NIH-2° supernatant
and
monitored for RT activity. 293 cells were exposed to the same
supernatant as a positive control for these experiments. In addition,
cell supernatants of target cells were monitored for low-level
virus
production by RT-PCR to detect viral RNA. As shown in Table
4, PERV-NIH-2°-derived virus did not
infect any of the cell lines
examined as efficiently as control 293 cells, although all cells
were positive by RT-PCR after exposure to the
PERV-NIH-2° virus
supernatant. Only low levels of RT activity were
observed in the
MiCL.1 and CRFK cultures, while RT activity was not
above background
levels in the other target cells exposed to PERV. The
PG-4 cultures
resulted in a peak level of RT activity of 9,733 cpm of
[
3H]TTP incorporated at 3 weeks that by 5 weeks was
reduced to 2,344
cpm of [
3H]TTP incorporated.
Analysis of the susceptibility of human adherent cell lines to
infection by PERV.
A range of human cell lines derived from
different tissue or cell types were exposed to PERV-NIH-2°
pseudotypes and assayed for
-galactosidase expression. All of the
cell lines examined except CaKi-1 were susceptible to various degrees
to infection as measured by
-galactosidase expression (Table
5). For example, the PERV pseudotype
titer observed on HOS or HeLa cells was 20- to 100-fold lower than that
observed on 293 cells, while the pseudotype titer observed on HepG2 or
HT1080 cells was in the same range as that observed on 293 cells. When
cells were exposed to PERV pseudotype supernatant and cultured for 8 weeks, only HepG2 and HT1080 cells were permissive to productive
infection as determined by RT assay, but the levels of RT activity were
quite low relative to those measured in control 293 cultures (Tables 4
and 5).
Analysis of the susceptibility of human hematopoietic cells to
infection by PERV.
To assess whether primary hPBMC were
susceptible to infection by PERV, PHA-activated hPBMC were cocultured
with irradiated PERV-NIH-2° producer cells and maintained in
IL-2-containing medium for 8 weeks (see Materials and Methods). No RT
activity above background levels or viral RNA as measured by RT-PCR was
detected during the course of the experiment (data not shown). Since
maintenance of the PHA-activated hPBMC in IL-2 during the course of the
experiment biases the culture conditions toward the proliferation of T
cells, other hematopoietic lineages that are susceptible to infection may not have been represented. To investigate the possibility that
other hematopoietic lineages would be permissive for infection, a
number of human hematopoietic cell lines representing the T-cell, B-cell, myeloid, and NK cell lineages were analyzed for susceptibility to PERV infection by coculture with irradiated 293/PERV-NIH-2° producer cells. Supernatants from the cocultures containing either M14
(T-cell lineage), Jurkat (T-cell lineage), or K562 (myeloid lineage)
cells or the NK cell line YTN10 remained negative for RT activity
during the 8-week course of the experiment, although viral RNA could be
detected by RT-PCR throughout the experiment (data not shown). Figure
3 shows RT activity for the cocultures containing the T-cell line Molt 4, the B-cell lines Daudi and Raji, and
the myeloid cell line U937. By 4 weeks postcoculture, the RT activity
in the Molt 4- and U937-containing cocultures was positive and
continued progressively to increase throughout the period of the
coculture. In contrast, the RT activity for both the Raji and Daudi
sets of cocultures plateaud by 4 weeks postculture and never rose to a
level comparable to that for either the Molt 4 or U937 coculture. The
results from this experiment suggest that the Molt 4, Daudi, Raji, and
U937 cell lines were permissive for productive infection by PERV.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
RT activity observed in cocultures of 293/PERV-NIH-2°
producer cells and human hematopoietic cell lines. Data points
represent [3H]TTP incorporated in an RT assay measured in
cell supernatants sampled at the times indicated after coculture of
293/PERV-NIH-2° producer cells with each of the cell lines indicated.
Values of [3H]TTP incorporation for parallel
mock-infected controls were subtracted from the values obtained in
matched cocultures.
|
|
We then cocultured the RT-positive hematopoietic cell lines with
primary hPBMC, hypothesizing that a virus population that
more
efficiently infects primary hematopoietic cells may have
been selected
in the susceptible hematopoietic cell lines. Before
initiating this
experiment, we determined the conditions optimal
for lethal irradiation
for each of the RT-positive Daudi, Molt
4, and U937 cell lines as
described in Materials and Methods.
We then used lethally irradiated
RT-positive Daudi, Molt 4, and
U937 cells as virus producer cells in
cocultures with primary
hPBMC activated with PHA or with human 293 cells as positive controls.
By 2 weeks postcoculture, each of the
cocultures containing 293
cells as target cells became significantly RT
positive (>7,000
cpm); by 3 weeks, the RT activity in each of these
cultures increased
to >20,000 cpm. In contrast, none of the cocultures
containing
the hPBMC demonstrated RT activity higher than that of
negative
control cultures over the course of the experiment. Although
viral
RNA was detected by RT-PCR in the supernatant of cultures sampled
1 to 2 weeks postexposure, the supernatant was negative for viral
RNA
by RT-PCR by 3 weeks and remained so out to the 8-week time
point. The
positive RT-PCR results obtained at the early time
points most likely
reflect presence of residual irradiated virus
producer cells which
disappear from the culture at the later time
points, rather than
infected
cells.
 |
DISCUSSION |
We have pursued our initial observation that pPBMC, upon
activation, release a retrovirus infectious for a human cell line with
a broader analysis of the in vitro host range of the PERV population
isolated from primary pPBMC. Use of pseudotypes bearing the gene for
-galactosidase allowed us to show that additional passage of the
initial PERV isolate (PERV-NIH-1°) through a human cell line produced
a virus (PERV-NIH-2°) with an approximately four- to eightfold
increase in titer on human 293 cells relative to the PERV-NIH-1° virus.
In an effort to understand the mechanism for the observed increase in
titer of infectious virus present in the PERV-NIH-2° supernatants
relative to the PERV-NIH-1° supernatant, we examined several aspects
of the viral populations present. We found that the particle counts of
the two supernatants were only twofold different whereas RT activities
were fourfold different, demonstrating that there is a higher rate of
defective particles present in the PERV-NIH-1° supernatant (i.e.,
particles detected by EM that may be RT negative). However, the
additional observation that the PERV-NIH-2° virions had enhanced
infectivity on 293 cells even greater than the difference in RT
activity (eightfold difference in infectious titer) suggested an
additional mechanism. Indeed, PCR analysis of the envelope class
demonstrated that the second passage in 293 cells seemed to exclude the
PERV-C envelope class, most likely due to the inability of virions
coated with PERV-C to infect 293 cells (13). Presumably
genomes encoding PERV-C were carried from the activated pPBMC into the
initial 293 cells by pseudotyping. Besides the shift away from
PERV-C-containing genomes, we could not detect a mutation in the
envelope-coding region by sequence analysis that may also allow for the
increase in infectious titer of PERV-NIH-2° virions on 293 cells.
However, changes in other regions of the genome, such as the long
terminal repeat or gag-pol coding regions, cannot be
excluded as contributing to the enhanced infection efficiencies
following passaging in human cells. Together these results suggest that
a greater number of genomes that are either defective or incapable of
infecting 293 cells (i.e., carrying PERV-C envelope) are present in the PERV-NIH-1° culture than in the PERV-NIH-2° culture, thus
accounting for the lower titer of infectious PERV-NIH-1° pseudotypes
relative to the PERV-NIH-2° pseudotypes on 293 cells.
The deduced amino acid sequence of the envelope glycoprotein derived
from PERV-NIH-1° virions is similar to the previously reported PERV-A
envelope sequence (4), with the exception of the C-terminal
90 amino acid residues of the TM envelope protein, which are virtually
identical to those of PERV-C (1, 13). This observation
demonstrates the presence of at least one additional variant of
envelope in addition to those previously reported. It remains to be
determined whether the envelope reported here is in the same receptor
interference group as the PERV-A class, although one would expect so
since the entire SU is most like that of PERV-A (4). Of the
cell lines examined in our study that are common to those presented in
the report of Takeuchi and coworkers, the in vitro host range of
PERV-NIH is mostly in agreement with that reported for PERV-A, with the
notable exception of canine D17 cells (13).
In this study, we analyzed cells from different species and tissues for
in vitro susceptibility to infection by PERV-NIH-2° pseudotypes.
Based on the initial assessment of infectivity by expression of
-galactosidase, we found that mouse- and rat-derived cell lines as
well as cell lines derived from rabbit, dog, cow, and rhesus monkey
were all resistant to infection relative to 293 cells. In contrast, of
the human adherent cell lines examined, only CaKi-1, derived from a
kidney carcinoma, was not susceptible to infection by PERV-NIH-2°
pseudotypes. This marked difference in susceptibility to infection
between the two human kidney cell lines examined, CaKi-1 and 293 cells,
argues against the human tissue source as a predictor of whether a
target cell is susceptible or resistant to infection by PERV-NIH-2°.
The observation that 293 cells are efficiently infected while CaKi-1
cells are resistant to infection by PERV-NIH-2° may be attributable
to differences in their phenotypic status. For example, the
transformation of 293 cells by adenovirus and the expression of certain
adenovirus proteins may alter the profile of cell surface proteins,
resulting in expression of the PERV receptor which may not be expressed on kidney cells under other conditions. Alternatively, the fact that
293 cells are embryo derived whereas CaKi-1 is a tumor-derived cell
line may also have an impact on the expression of cell surface proteins.
We determined that target cells that were susceptible to PERV-NIH-2°
pseudotype infection as measured by
-galactosidase expression were
not always productively infected, e.g., capable of producing replication-competent progeny virions. We used two tools to measure productive infection: an RT assay, which provided an insensitive assessment of viral replication, and a more sensitive RT-PCR assay. The
detection of viral RNA by RT-PCR in the absence of detectable RT
activity suggests low-level virus production in the absence of
productive viral replication. This pattern was observed with the feline
cell lines AK-D and Fc3TG, human colorectal adenocarcinoma CaCO-2
cells, the human T-cell lines Jurkat and M14, the NK cell line YTN10,
and the myeloid cell line K56. These results are consistent with the
conclusion that these cell lines are not permissive for productive
infection. Some cell lines, such as feline CRFK, human fibrosarcoma
HT1080, and the B-cell lines Daudi and Raji, were positive for RT
activity. However, the activity measured in these cultures remained at
low levels (i.e., <2,000 to 3,000 cpm) and did not increase during the
8-week culture period. This pattern may reflect decreased
susceptibility to viral infection and/or viral replication and spread.
Exposure of mink lung fibroblast Mv1Lu, feline PG-4, and HepG2
hepatoblastoma cells, the Molt 4 T-cell line, and the promyelomonocytic
cell line U937 to PERV-NIH-2° virions or cells resulted in RT
activity that increased over time, suggesting more efficient productive
infection of these cell types. Collectively, these data suggest that
PERV-NIH, isolated from activated pPBMC, is not highly infectious in
vitro. However, an alternative explanation may be a lack of optimal
methods for culturing the virus in vitro, and therefore these results
may not reflect PERV infectivity in vivo.
One goal of this study was to survey cell lines from a variety of
species to determine which species-derived target cells supported
infection and replication by PERV-NIH as a first step in identifying a
candidate animal model for assessing in vivo infectivity and
pathogenicity. We found that the in vitro host range is quite
restricted. Our analysis of a spectrum of mouse, rat, rabbit, and dog
cell lines suggests that these animals would not serve as useful
models. In addition, analysis of nonhuman primate cell lines described
here and by others (13) suggests that nonhuman primates may
not be permissive hosts for in vivo infectivity studies, assuming that
our in vitro findings translate to the in vivo setting. This has been
confirmed by one group who showed no evidence for infection in baboons
after exposure to PERV-expressing porcine endothelial cells
(8). The only cells productively infected, albeit
inefficiently compared with 293 cells, were those derived from cat and
mink. In vitro selection of a virus that more efficiently infects cat
or mink cells may be an approach needed to enhance the development of
an animal model system. For example, it was shown that after long-term
passage of Rous sarcoma virus on nonpermissive quail cells, a variant that was able to infect quail cells could be isolated (14). A similar approach may be taken to isolate a variant that can more
efficiently infect cells from the species of choice for analysis in
that animal model.
We found no evidence for infection by PERV-NIH-2° of primary hPBMC
under the culture conditions used in this study. In an extension of
this analysis, we examined cell lines derived from different
hematopoietic lineages and generally did not observe a correlation
between susceptibility and lineage. Infection of the T-cell line Molt 4 resulted in high levels of RT activity, while the other T-cell lines
examined, Jurkat and M14, were not permissive for productive infection.
Similarly, the myelomonocytic cell line U937 was permissive for
infection, while the myeloid cell line K562 was not. Only for B cells
were both B-cell lines examined, Daudi and Raji, shown to be permissive
for viral replication. These findings suggest that susceptibility to
infection may be more dependent on other factors such as the means of
transformation (all of these cell lines are transformed) or in vitro
culture conditions, rather than lineage per se. This finding echoes the results observed for the two human kidney cell lines in this study, CaKi-1 and 293. In an effort to maximize the possibility of infecting primary cells, we used the RT-positive human hematopoietic cell lines
Molt 4, Daudi, and U937 as virus producers in a coculture with human
PBMC. Under the culture conditions of this experiment, the PBMC
remained resistant to infection. In toto, these results underscore the
need for caution in interpreting data from xenotransplant clinical
trials where recipients are analyzed for evidence of infection by
analysis of hPBMC for presence of proviral DNA sequences, since these
cells may not be susceptible to infection in vivo.
Our analysis of the in vitro host range of PERV(es) complements and
extends those analyses previously reported, for example, by Takeuchi
and coworkers (13). In particular, our results demonstrate the utility of using pseudotypes for initial assessment of
susceptibility to infection followed by monitoring for the spread of
infection to demonstrate whether the cells are permissive for viral
replication and not just for viral entry and expression. Further study
is needed to understand the viral and cellular contributions to
inefficient replication in vitro. In addition, these studies
demonstrate that development of permissive animal models will be
necessary to enhance our understanding of the in vivo infectivity
properties of this virus.
 |
ACKNOWLEDGMENTS |
We thank Junji Yodoi, Kyoto University, for the gift of a cell
line used in this study. We are grateful for technical insights provided by Judy Arcidiacono and Keizo Furuke. Finally, we thank Maribeth Eiden and Eda Bloom for helpful discussions and reviews of the manuscript.
This work was supported in part by the Siebens Foundation, under the
Harold W. Siebens Research Scholar Program and the Mayo Foundation
(M.J.F.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Building 29B,
Room 2NN11, 8800 Rockville Pike, Bethesda, MD 20892. Phone: (301)
827-0481. Fax: (301) 827-0449. E-mail:
wilsonc{at}cber.fda.gov.
 |
REFERENCES |
| 1.
|
Akiyoshi, D. E.,
M. Denaro,
H. Zhu,
J. L. Greenstein,
P. Banerjee, and J. A. Fishman.
1998.
Identification of a full-length cDNA for an endogenous retrovirus of miniature swine.
J. Virol.
72:4503-4507[Abstract/Free Full Text].
|
| 2.
|
Armstrong, J. A.,
J. S. Porterfield, and A. T. D. Madrid.
1971.
C-type virus particles in pig kidney cell lines.
J. Gen. Virol.
10:195-198[Abstract/Free Full Text].
|
| 3.
|
Kawakami, T. G.,
G. V. Kollias, Jr., and C. Holmberg.
1980.
Oncogenicity of gibbon type-C myelogenous leukemia virus.
Int. J. Cancer
25:641-646[Medline].
|
| 4.
|
Le Tissier, P.,
J. P. Stoye,
Y. Takeuchi,
C. Patience, and R. A. Weiss.
1997.
Two sets of human-tropic pig retroviruses.
Nature
389:681-682[CrossRef][Medline].
|
| 5.
|
Leverett, B. D.,
K. B. Farrell,
M. V. Eiden, and C. A. Wilson.
1998.
Entry of amphotropic murine leukemia virus is influenced by residues in the putative second extracellular domain of the human form of its receptor, Pit2.
J. Virol.
72:4956-4961[Abstract/Free Full Text].
|
| 6.
|
Lieber, M. M.,
C. J. Sherr,
R. E. Benveniste, and G. J. Todaro.
1975.
Biologic and immunologic properties of porcine type C viruses.
Virology
66:616-619[CrossRef][Medline].
|
| 7.
|
Martin, U.,
V. Kiessig,
J. Blusch,
A. Haverich,
K. von der Helm,
T. Herden, and G. Steinhoff.
1998.
Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells.
Lancet
352:692-694[CrossRef][Medline].
|
| 8.
|
Martin, U.,
G. Steinhoff,
V. Kiessig,
M. Chikobava,
M. Anssar,
T. Morschheuser,
B. Lapin, and A. Haverich.
1999.
Porcine endogenous retrovirus is transmitted neither in vivo nor in vitro from porcine endothelial cells to baboons.
Transplant. Proc.
31:913-914[CrossRef][Medline].
|
| 9.
|
McLachlin, J. R.,
N. Mittereder,
M. B. Daucher,
M. Kadan, and M. A. Eglitis.
1993.
Factors affecting retroviral vector function and structural integrity.
Virology
195:1-5[CrossRef][Medline].
|
| 10.
|
Niwa, O.
1985.
Suppression of the hypomethylated Moloney leukemia virus genome in undifferentiated teratocarcinoma cells and inefficiency of transformation by a bacterial gene under control of the long terminal repeat.
Mol. Cell. Biol.
5:2325-2331[Abstract/Free Full Text].
|
| 11.
|
Patience, C.,
Y. Takeuchi, and R. A. Weiss.
1997.
Infection of human cells by an endogenous retrovirus of pigs.
Nat. Med.
3:282-286[CrossRef][Medline].
|
| 12.
|
Ramsdell, F. J.,
H. Shau, and S. H. Golub.
1988.
Role of proliferation in LAK cell development.
Cancer Immunol. Immunother.
26:139-144[Medline].
|
| 13.
|
Takeuchi, Y.,
C. Patience,
S. Magre,
R. A. Weiss,
P. T. Banerjee,
P. Le Tissier, and J. P. Stoye.
1998.
Host range and interference studies of three classes of pig endogenous retrovirus.
J. Virol.
72:9986-9991[Abstract/Free Full Text].
|
| 14.
|
Taplitz, R. A., and J. M. Coffin.
1997.
Selection of an avian retrovirus mutant with extended receptor usage.
J. Virol.
71:7814-7819[Abstract].
|
| 15.
|
Todaro, G. J.,
R. E. Benveniste,
M. M. Lieber, and C. J. Sherr.
1974.
Characterization of a type C virus released from the porcine cell line PK(15).
Virology
58:65-74[CrossRef][Medline].
|
| 16.
|
Weiss, R. A., and A. L. Long.
1977.
Phenotypic mixing between avian and mammalian RNA tumor viruses. I. Envelope pseudotypes of Rous sarcoma virus.
Virology
76:826-834[CrossRef][Medline].
|
| 17.
|
Wilson, C., and M. Eiden.
1991.
Viral and cellular factors governing hamster cell infection by murine and gibbon ape leukemia viruses.
J. Virol.
65:5975-5982[Abstract/Free Full Text].
|
| 18.
|
Wilson, C.,
S. Wong,
J. Muller,
C. Davidson,
T. Rose, and P. Burd.
1998.
Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells.
J. Virol.
72:3082-3087[Abstract/Free Full Text].
|
| 19.
|
Wilson, C. A.,
K. B. Farrell, and M. V. Eiden.
1994.
Comparison of cDNAs encoding the gibbon ape leukaemia virus receptor from susceptible and non-susceptible murine cells.
J. Gen. Virol.
75:1901-1908[Abstract/Free Full Text].
|
| 20.
|
Yodoi, J.,
K. Teshigawara,
T. Nikaido,
F. Fukui,
T. Noma,
T. Hongo,
M. Takigawa,
M. Sasaki,
N. Minato,
M. Tsudo,
T. Uchiyama, and M. Maeda.
1985.
TCGF (IL-2)-receptor inducing factor(s). I. Regulation of IL-2 receptor on natural killer-like cell line (YT cells).
J. Immunol.
134:1623-1630[Abstract].
|
Journal of Virology, January 2000, p. 49-56, Vol. 74, No. 1
0022-538X/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wood, A., Webb, B. L. J., Bartosch, B., Schaller, T., Takeuchi, Y., Towers, G. J.
(2009). Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5{alpha} proteins including human TRIM5{alpha}. J. Gen. Virol.
90: 702-709
[Abstract]
[Full Text]
-
Argaw, T., Figueroa, M., Salomon, D. R., Wilson, C. A.
(2008). Identification of Residues outside of the Receptor Binding Domain That Influence the Infectivity and Tropism of Porcine Endogenous Retrovirus. J. Virol.
82: 7483-7491
[Abstract]
[Full Text]
-
Moalic, Y., Blanchard, Y., Felix, H., Jestin, A.
(2006). Porcine Endogenous Retrovirus Integration Sites in the Human Genome: Features in Common with Those of Murine Leukemia Virus. J. Virol.
80: 10980-10988
[Abstract]
[Full Text]
-
Martina, Y., Marcucci, K. T., Cherqui, S., Szabo, A., Drysdale, T., Srinivisan, U., Wilson, C. A., Patience, C., Salomon, D. R.
(2006). Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection.. J. Virol.
80: 3135-3146
[Abstract]
[Full Text]
-
Harrison, I., Takeuchi, Y., Bartosch, B., Stoye, J. P.
(2004). Determinants of High Titer in Recombinant Porcine Endogenous Retroviruses. J. Virol.
78: 13871-13879
[Abstract]
[Full Text]
-
Bartosch, B., Stefanidis, D., Myers, R., Weiss, R., Patience, C., Takeuchi, Y.
(2004). Evidence and Consequence of Porcine Endogenous Retrovirus Recombination. J. Virol.
78: 13880-13890
[Abstract]
[Full Text]
-
Scobie, L., Taylor, S., Logan, N. A., Meikle, S., Onions, D., Patience, C., Quinn, G.
(2004). Characterization of germline porcine endogenous retroviruses from Large White pig. J. Gen. Virol.
85: 2421-2428
[Abstract]
[Full Text]
-
Quinn, G., Wood, J. C., Ryan, D. J. J., Suling, K. M., Moran, K. M., Kolber-Simonds, D. L., Greenstein, J. L., Schuurman, H.-J., Hawley, R. J., Patience, C.
(2004). Porcine Endogenous Retrovirus Transmission Characteristics of Galactose {alpha}1-3 Galactose-Deficient Pig Cells. J. Virol.
78: 5805-5811
[Abstract]
[Full Text]
-
Scobie, L., Taylor, S., Wood, J. C., Suling, K. M., Quinn, G., Meikle, S., Patience, C., Schuurman, H.-J., Onions, D. E.
(2004). Absence of Replication-Competent Human-Tropic Porcine Endogenous Retroviruses in the Germ Line DNA of Inbred Miniature Swine. J. Virol.
78: 2502-2509
[Abstract]
[Full Text]
-
Klymiuk, N., Muller, M., Brem, G., Aigner, B.
(2003). Recombination analysis of human-tropic porcine endogenous retroviruses. J. Gen. Virol.
84: 2729-2734
[Abstract]
[Full Text]
-
Walles, T., Lichtenberg, A., Puschmann, C., Leyh, R., Wilhelmi, M., Kallenbach, K., Haverich, A., Mertsching, H.
(2003). In vivo model for cross-species porcine endogenous retrovirus transmission using tissue engineered pulmonary arteries. Eur. J. Cardiothorac. Surg.
24: 358-363
[Abstract]
[Full Text]
-
Ericsson, T. A., Takeuchi, Y., Templin, C., Quinn, G., Farhadian, S. F., Wood, J. C., Oldmixon, B. A., Suling, K. M., Ishii, J. K., Kitagawa, Y., Miyazawa, T., Salomon, D. R., Weiss, R. A., Patience, C.
(2003). Identification of receptors for pig endogenous retrovirus. Proc. Natl. Acad. Sci. USA
100: 6759-6764
[Abstract]
[Full Text]
-
Wilson, C. A., Laeeq, S., Ritzhaupt, A., Colon-Moran, W., Yoshimura, F. K.
(2002). Sequence Analysis of Porcine Endogenous Retrovirus Long Terminal Repeats and Identification of Transcriptional Regulatory Regions. J. Virol.
77: 142-149
[Abstract]
[Full Text]
-
Scheef, G., Fischer, N., Flory, E., Schmitt, I., Tonjes, R. R.
(2002). Transcriptional Regulation of Porcine Endogenous Retroviruses Released from Porcine and Infected Human Cells by Heterotrimeric Protein Complex NF-Y and Impact of Immunosuppressive Drugs. J. Virol.
76: 12553-12563
[Abstract]
[Full Text]
-
Ritzhaupt, A., van der Laan, L. J. W., Salomon, D. R., Wilson, C. A.
(2002). Porcine Endogenous Retrovirus Infects but Does Not Replicate in Nonhuman Primate Primary Cells and Cell Lines. J. Virol.
76: 11312-11320
[Abstract]
[Full Text]
-
Bartosch, B., Weiss, R. A., Takeuchi, Y.
(2002). PCR-based cloning and immunocytological titration of infectious porcine endogenous retrovirus subgroup A and B. J. Gen. Virol.
83: 2231-2240
[Abstract]
[Full Text]
-
Blusch, J. H., Seelmeir, S., von der Helm, K.
(2002). Molecular and Enzymatic Characterization of the Porcine Endogenous Retrovirus Protease. J. Virol.
76: 7913-7917
[Abstract]
[Full Text]
-
Lee, J.-H., Webb, G. C., Allen, R. D. M., Moran, C.
(2002). Characterizing and Mapping Porcine Endogenous Retroviruses in Westran Pigs. J. Virol.
76: 5548-5556
[Abstract]
[Full Text]
-
Johnston, J. B., Power, C.
(2002). Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. J. Virol.
76: 3626-3636
[Abstract]
[Full Text]
-
Niebert, M., Rogel-Gaillard, C., Chardon, P., Tonjes, R. R.
(2002). Characterization of Chromosomally Assigned Replication-Competent Gamma Porcine Endogenous Retroviruses Derived from a Large White Pig and Expression in Human Cells. J. Virol.
76: 2714-2720
[Abstract]
[Full Text]
-
Oldmixon, B. A., Wood, J. C., Ericsson, T. A., Wilson, C. A., White-Scharf, M. E., Andersson, G., Greenstein, J. L., Schuurman, H.-J., Patience, C.
(2002). Porcine Endogenous Retrovirus Transmission Characteristics of an Inbred Herd of Miniature Swine. J. Virol.
76: 3045-3048
[Abstract]
[Full Text]
-
Takefman, D. M., Spear, G. T., Saifuddin, M., Wilson, C. A.
(2002). Human CD59 Incorporation into Porcine Endogenous Retrovirus Particles: Implications for the Use of Transgenic Pigs for Xenotransplantation. J. Virol.
76: 1999-2002
[Abstract]
[Full Text]
-
Herring, C., Quinn, G., Bower, R., Parsons, N., Logan, N. A., Brawley, A., Elsome, K., Whittam, A., Fernandez-Suarez, X. M., Cunningham, D., Onions, D., Langford, G., Scobie, L.
(2001). Mapping Full-Length Porcine Endogenous Retroviruses in a Large White Pig. J. Virol.
75: 12252-12265
[Abstract]
[Full Text]
-
Scheef, G., Fischer, N., Krach, U., Tonjes, R. R.
(2001). The Number of a U3 Repeat Box Acting as an Enhancer in Long Terminal Repeats of Polytropic Replication-Competent Porcine Endogenous Retroviruses Dynamically Fluctuates during Serial Virus Passages in Human Cells. J. Virol.
75: 6933-6940
[Abstract]
[Full Text]
-
Krach, U., Fischer, N., Czauderna, F., Tönjes, R. R.
(2001). Comparison of Replication-Competent Molecular Clones of Porcine Endogenous Retrovirus Class A and Class B Derived from Pig and Human Cells. J. Virol.
75: 5465-5472
[Abstract]
[Full Text]
-
Takefman, D. M., Wong, S., Maudru, T., Peden, K., Wilson, C. A.
(2001). Detection and Characterization of Porcine Endogenous Retrovirus in Porcine Plasma and Porcine Factor VIII. J. Virol.
75: 4551-4557
[Abstract]
[Full Text]
-
Specke, V., Tacke, S. J., Boller, K., Schwendemann, J., Denner, J.
(2001). Porcine endogenous retroviruses: in vitro host range and attempts to establish small animal models. J. Gen. Virol.
82: 837-844
[Abstract]
[Full Text]
-
Ericsson, T., Oldmixon, B., Blomberg, J., Rosa, M., Patience, C., Andersson, G.
(2001). Identification of Novel Porcine Endogenous Betaretrovirus Sequences in Miniature Swine. J. Virol.
75: 2765-2770
[Abstract]
[Full Text]
-
Patience, C., Switzer, W. M., Takeuchi, Y., Griffiths, D. J., Goward, M. E., Heneine, W., Stoye, J. P., Weiss, R. A.
(2001). Multiple Groups of Novel Retroviral Genomes in Pigs and Related Species. J. Virol.
75: 2771-2775
[Abstract]
[Full Text]
-
Qari, S. H., Magre, S., García-Lerma, J. G., Hussain, A. I., Takeuchi, Y., Patience, C., Weiss, R. A., Heneine, W.
(2001). Susceptibility of the Porcine Endogenous Retrovirus to Reverse Transcriptase and Protease Inhibitors. J. Virol.
75: 1048-1053
[Abstract]
[Full Text]
-
Bösch, S., Arnauld, C., Jestin, A.
(2000). Study of Full-Length Porcine Endogenous Retrovirus Genomes with Envelope Gene Polymorphism in a Specific-Pathogen-Free Large White Swine Herd. J. Virol.
74: 8575-8581
[Abstract]
[Full Text]
-
Blusch, J. H., Patience, C., Takeuchi, Y., Templin, C., Roos, C., Von Der Helm, K., Steinhoff, G., Martin, U.
(2000). Infection of Nonhuman Primate Cells by Pig Endogenous Retrovirus. J. Virol.
74: 7687-7690
[Abstract]
[Full Text]
-
Czauderna, F., Fischer, N., Boller, K., Kurth, R., Tönjes, R. R.
(2000). Establishment and Characterization of Molecular Clones of Porcine Endogenous Retroviruses Replicating on Human Cells. J. Virol.
74: 4028-4038
[Abstract]
[Full Text]